<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xu J</submitter><funding>Kashi Regional Science and Technology Program Projects</funding><funding>the Hospital Scientific research project of the First People's Hospital of Kashi</funding><funding>Dedicated funding for stem cell research project of the First People's Hospital of Kashi</funding><pagination>28339</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12322009</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>Pulmonary fibrosis (PF) is a progressive, irreversible disease with limited effective treatments. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) have recently shown promise in PF therapy. This study evaluated the therapeutic effects and mechanisms of UC-MSCs combined with pirfenidone (PFD) in a bleomycin-induced PF model. C57BL/6 mice were divided into nine groups: control, model, PFD (100 mg/kg), UC-MSCs (0.5 × 10&lt;sup>6&lt;/sup>, 1.0 × 10&lt;sup>6&lt;/sup>, and 2.0 × 10&lt;sup>6&lt;/sup> cells per animal), and PFD (100 mg/kg) + UC-MSCs (0.5 × 10&lt;sup>6&lt;/sup>, 1.0 × 10&lt;sup>6&lt;/sup>, and 2.0 × 10&lt;sup>6&lt;/sup> cells per animal). The model was established by intratracheal bleomycin instillation. PFD was administered intraperitoneally twice daily from day 4 to 21 in the PFD and PFD + UC-MSCs grou</pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis.</pubmed_title><pmcid>PMC12322009</pmcid><funding_grant_id>2023-13</funding_grant_id><funding_grant_id>KDYY202312</funding_grant_id><funding_grant_id>KS2023012</funding_grant_id><funding_grant_id>KS2022033</funding_grant_id><pubmed_authors>Abudureheman Z</pubmed_authors><pubmed_authors>Zou X</pubmed_authors><pubmed_authors>Zhong X</pubmed_authors><pubmed_authors>Xue L</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Gong H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis.</name><description>Pulmonary fibrosis (PF) is a progressive, irreversible disease with limited effective treatments. Human umbilical cord-derived mesenchymal stem cells (UC-MSCs) have recently shown promise in PF therapy. This study evaluated the therapeutic effects and mechanisms of UC-MSCs combined with pirfenidone (PFD) in a bleomycin-induced PF model. C57BL/6 mice were divided into nine groups: control, model, PFD (100 mg/kg), UC-MSCs (0.5 × 10&lt;sup>6&lt;/sup>, 1.0 × 10&lt;sup>6&lt;/sup>, and 2.0 × 10&lt;sup>6&lt;/sup> cells per animal), and PFD (100 mg/kg) + UC-MSCs (0.5 × 10&lt;sup>6&lt;/sup>, 1.0 × 10&lt;sup>6&lt;/sup>, and 2.0 × 10&lt;sup>6&lt;/sup> cells per animal). The model was established by intratracheal bleomycin instillation. PFD was administered intraperitoneally twice daily from day 4 to 21 in the PFD and PFD + UC-MSCs grou</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-04-08T23:20:28.703Z</modification><creation>2026-04-07T13:17:42.582Z</creation></dates><accession>S-EPMC12322009</accession><cross_references><pubmed>40760158</pubmed><doi>10.1038/s41598-025-14286-4</doi></cross_references></HashMap>